Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend. | LAS VEGAS—Demand for GLP-1s has not ...

The end-to-end program is meant to help employees more seamlessly access and manage their GLP-1 prescriptions.

Noom is rolling out two new solutions that aim to make it easier for employers and members to manage GLP-1s, and it's teaming ...

Leveraging Waltz Connect by Waltz Health, the two industry leaders together are engineering a joint solution that will provide an end-to-end program that helps employees more seamlessly access and ...

Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help reduced the rate of overdoses and ...

Noom says the new scanning technology developed in partnership with Prism Labs will provide “actionable health insights”.

Recognizing women's unique health needs, Noom's Women’s Health features include content, tools, and a coach-led community ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

GLP-1 drugs such as Wegovy and Ozempic (semaglutide) and Zepbound (tirzepatide) may offer benefits that extend beyond aiding in weight loss in people who have type 2 diabetes or obesity.